Preexposure prophylaxis for HIV infection among African women

New England Journal of Medicine

Volumn 367, Issue 5, 2012, Pages 411-422

  Van Damme, Lut ^a   Corneli, Amy ^a   Ahmed, Khatija ^c   Agot, Kawango ^e   Lombaard, Johan ^d   Kapiga, Saidi ^f,g   Malahleha, Mookho ^c   Owino, Fredrick ^e   Manongi, Rachel ^f   Onyango, Jacob ^e   Temu, Lucky ^f   Monedi, Modie Constance ^c   Mak'Oketch, Paul ^e   Makanda, Mankalimeng ^d   Reblin, Ilse ^d   Makatu, Shumani Elsie ^c   Saylor, Lisa ^a   Kiernan, Haddie ^a   Kirkendale, Stella ^a   Wong, Christina ^a   Grant, Robert ^h   Kashuba, Angela ^b   Nanda, Kavita ^a   Mandala, Justin ^a   Fransen, Katrien ⁱ   Deese, Jennifer ^a   Crucitti, Tania ⁱ   Mastro, Timothy D ^a   Taylor, Douglas ^a   more..

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b University of North Carolina   (United States)

^c Setshaba Research Centre   (South Africa)

^d JOSHA Research   (South Africa)

^e IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^f KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; PLACEBO; TENOFOVIR DISOPROXIL;

ABORTION; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG OVERDOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEGRO; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; RISK ASSESSMENT; SEROCONVERSION; SEXUAL BEHAVIOR; SIDE EFFECT; TREATMENT DURATION; UROGENITAL ULCER; VIRUS LOAD; VOMITING; WOMEN'S HEALTH;

EID: 84864507852     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1202614     Document Type: Article

References (13)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
4. Mascolini M. FDA panel endorses Truvada for pre-exposure prophylaxis. International AIDS Society, May 12, 2012 (http://www.iasociety.org/Article.aspx? elementId=14505).
5. Weir SS, Tate J, Hileman SB, et al. Priorities for local AIDS control efforts: a manual for implementing the PLACE method. Chapel Hill, NC: Carolina Population Center, 2005.
6. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Bethesda, MD: National Institute of Allergy and Infectious Diseases, Division of AIDS, December 28, 2004.
7. EAST: software for advanced clinical trial design, simulation, and monitoring, version 5.2. Cambridge, MA: Cytel Statistical Software and Services, 2008.
8. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4.
9. Anderson P, Liu L, Buchbinder S, et al. Intracellular tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. abstract.
10. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 2011 December 6 (Epub ahead of print).
11. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. abstract.
12. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Pittsburgh: Microbicides Trial Network, September 28, 2011 (http://www.mtnstopshiv.org/node/3619).
13. Abdool Karim S. Biological mechanisms and efficacy. Presented at the International Microbicides Conference, Sydney, April 15-18, 2012.